Arcturus Therapeutics Holdings Inc (ARCT) Implied Volatility Current

Tracking ARCT implied volatility helps you identify when options premiums on Arcturus Therapeutics Holdings Inc are historically cheap or expensive, and where the best trades are hiding. Arcturus Therapeutics Holdings Inc implied volatility reflects the market's expectation of future price movement: when ARCT IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Arcturus Therapeutics Holdings Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ARCT, tracking metrics like ARCT IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ARCT signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc.

to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ARCT implied volatility sits today versus where it has been. Our scanner ranks Arcturus Therapeutics Holdings Inc implied volatility against its historical range, surfaces extremes in ARCT IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Arcturus Therapeutics Holdings Inc IV is rich or cheap — measure it, then act on it.